Testing empagliflozin for heart and kidney health
Treatments studied
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are in the hospital for heart failure (new or worsening).
- You have signs of acute kidney injury or a high level of a kidney protein called NGAL in your urine.
- You can start the study drug within 12 hours of the kidney injury diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial tests whether empagliflozin, a medication originally for diabetes, can help protect the remaining kidney function in people who have just started peritoneal dialysis. If you started dialysis within the last 3 months and still make some urine, this study may be a good fit.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
This study tests a pill called empagliflozin (commonly used for diabetes) to see if it can help people with chronic kidney disease who do not have diabetes. It looks at whether the drug can protect your blood vessels and slow down how quickly your kidneys get worse.
Hear when a new Empagliflozin in Cardiorenal Syndrome Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.